NCT04180436View on ClinicalTrials.gov

Pharmacokinetics of Rivaroxaban After Bariatric Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

June 21, 2022

Study Completion Date

June 27, 2022

Conditions
Bariatric SurgeryMorbid Obesity
Interventions
DRUG

rivaroxaban 20 mg once daily 8 days

Blood samples for the measurement of rivaroxaban PK parameters

Trial Locations (1)

29609

CHRU de Brest, Brest

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University Hospital, Brest

OTHER

NCT04180436 - Pharmacokinetics of Rivaroxaban After Bariatric Surgery | Biotech Hunter | Biotech Hunter